Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972854 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
A Phase 3 study, sponsored by Glaukos Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
NCT01972854 is a Phase 3 study that was terminated before completion, run by Glaukos Corporation. The registered enrollment target is 92 participants.
The verdict
NCT01972854, a Phase 3 study, was terminated before completion, sponsored by Glaukos Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.
Interventions
- DRUG riboflavin solution
- DRUG placebo solution
- DEVICE KXL System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-11 |
| Est. Completion | 2017-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01972854
The ClinicalTrials.gov registry entry for NCT01972854 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which riboflavin solution is the first listed.
NCT01972854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01972854 about?
NCT01972854 is a clinical study titled "Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus". The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.
What is the current status of trial NCT01972854?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2013-11. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01972854?
The interventions under investigation include: riboflavin solution (DRUG), placebo solution (DRUG), KXL System (DEVICE).
Who is sponsoring clinical trial NCT01972854?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.